ClinicalTrials.gg
CompletedNCT06713564Updated May 19, 2026

A Single Dose, Open-Label, Dose-escalation Study of the Safety and Imaging Characteristics of LS301-IT for Intraoperative Imaging of Lung Cancer

A Phase 1 interventional study of LS301-IT in Lung Cancers, sponsored by Integro Theranostics. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-19.

Sponsored by Integro Theranostics · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 2,459 studies in Lung Neoplasms with a site in United States — 422 open to participants now, 644 under way, 53 of them phase 3. Lung Neoplasms · United States.

Enrollment
1,327th of 1,905
24 · median 48
Started
2024
with 105 others
Phase 1
446 of 2,459
56 open now
Registered
2,261st of 2,459
by date

Among the 2,459 studies in Lung Neoplasms with a site in United States, this one is the 1,327th largest by enrollment of the 1,905 interventional ones that give a count, is one of 106 that started in 2024, is one of 446 in phase 1, and was the 2,261st registered.

Lung Neoplasms

5,424 studies on the registry are indexed under Lung Neoplasms; 1,345 are open to participants now.

Browse Lung Neoplasms studies →

Open to participants now

422 of the 2,459 studies in Lung Neoplasms with a site in United States are open now. Recruiting first, the newest first:

417 more — sign in →

All 422 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 995 Lung Neoplasms studies recruiting now, 682 (69%) set no upper age limit and 142 (14%) stop at 75 or younger; 45 take children under 18; 142 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,459 studies in Lung Neoplasms with a site in United States, or all of them as a file.
02

Study summary

The aim of this Phase 1b study is to investigate the safety and fluorescence signal of a single dose of LS301-IT, a novel fluorescence imaging agent developed by Integro Theranostics (IT), administered by slow intravenous (IV) administration in patients undergoing surgical thoracoscopy and resection of lung cancer. Safety is the primary objective of this study, followed by the evaluation of the fluorescence signal as it relates to dose level and dosing time interval.

Read the detailed description

This is a Phase 1b, open-label study to investigate the use of LS301-IT (investigational medicinal product [IMP]), a fluorescence imaging agent used for visualization of tumor margins and other suspicious nodules in patients with primary diagnosis, or a high clinical suspicion, for cancer in the lung based on CT, biopsy, or other imaging.

Up to 24 patients (4 dose cohorts, up to 6 patients each) for Phase 1b study (total of 24 patients maximum). There will be no stratification by dosing interval or lung cancer type (e.g., lung adenocarcinoma, lung squamous cell carcinoma).

As safety is the primary objective of this study, the safety of each dose level will be assessed by the Safety Review Committee (SRC). Based upon the safety results of the first cohort, the SRC will recommend to the Sponsor which dose levels of LS301-IT may be administered in subsequent cohorts.

03

Conditions studied

  • Lung Cancers

Browse trials for

Keywords

  • lung cancer imaging
  • lung cancer surgery
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • performance status of 0 to 2
  • Have a primary diagnosis, or a high clinical suspicion, for cancer in the lung based on CT, , or other imaging.
  • Are scheduled to undergo surgical thoracoscopy and resection of the lung.

Exclusion criteria

Exclusion Criteria:

  • for surgery or any medical condition that in the opinion of the investigator could jeopardize the safety of the subject
  • No planned surgical use of any other fluorescent optical imaging agent, or exposure to another optical imaging agent within 8 weeks prior to surgery

History of any drug-related or anaphylactic reactions, including those attributed to indocyanine green (ICG) or other agents used in the study, or known shellfish allergies.

Known sensitivity to near infrared light

Patients with impaired renal function as defined by a (CrCl) \<60 mL/min at Screening, according to the Cockcroft-Gault formula ((140 - age) × body weight/plasma creatinine × 72 (× 0.85 for female)

History, or presence in the at Screening, of any abnormalities including cardiac conduction abnormalities such as Fridericia's corrected (QTcF) > 470 ms

Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
Single (Outcomes assessor)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    LS301-IT Cohort -1

    0.0125 mg/kg LS301-IT administered by IV infusion over approximately 15 minutes the day before surgery

    Drug: LS301-IT

  • Experimental
    LS301-IT Cohort 1

    0.025 mg/kg LS301-IT administered by IV infusion over approximately 15 minutes the day before surgery

    Drug: LS301-IT

  • Experimental
    LS301-IT Cohort 2

    0.05 mg/kg LS301-IT administered by IV infusion over approximately 15 minutes the day before surgery

    Drug: LS301-IT

  • Experimental
    LS301-IT Cohort 3

    0.075 mg/kg LS301-IT administered by IV infusion over approximately 15 minutes the day before surgery

    Drug: LS301-IT

Interventions

  • LS301 is composed of: 1) a cyclic peptide that binds phosphorylated Annexin A2 (ANXA2) which is found on the surface of malignant cells typically located in solid tumors and in malignant lymph nodes; and 2) cypate, a near infrared (NIR) molecule conjugated to the peptide, which fluoresces when illuminated using NIR light.

06

What researchers measure

Primary outcomes

  1. Number of Patients with Dose Limiting Toxicities

    Dose Limiting Toxicity - Any CTCAE Grade 2, 3, 4, or 5 AE (any treatment emergent sign or symptom) at least possibly related to IMP will be considered a DLT, as well as any other AE deemed clinically relevant by the SRC.

    Time frame: 2 to 7 days after dosing

  2. Number of Patients that discontinue the study or have their surgery cancelled due to toxicity

    Treatment discontinuation and/or surgery cancellation due to toxicity (hypersensitivity reaction to LS301-IT)

    Time frame: From start of dosing to time of surgery

Other outcomes

  1. Maximum observed plasma concentration (Cmax) in ng/mL

    Cmax of LS301 and its main metabolite

    Time frame: Samples collected up to 24 hours after dosing

  2. Area under the plasma concentration time curve from time 0 extrapolated to infinite time (AUC0-∞ [AUCinf]) in ng*hr/mL

    AUC of LS301 in plasma.

    Time frame: Over 24 hours after dosing

  3. Area under the plasma concentration-time curve from time 0 to the last quantifiable plasma concentration (AUC0-t [AUClast]) in ng*hr/mL

    LS301 concentration in plasma

    Time frame: over 24 hours after dosing

  4. Time to reach maximal plasma concentration (Tmax) in minutes

    LS301 concentration in plasma

    Time frame: over 24 hours after dosing

  5. Elimination/apparent terminal elimination half- life (t1/2) in minutes

    LS301 concentration in plasma

    Time frame: 24 hours after dosing

07

Study locations

1 site
  • University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2024 to primary completion in May 2026, 17 months.

Of 128 industry-sponsored phase 1 interventional studies under Lung Neoplasms, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 57. This study's 17 months is below that.

Counting every sponsor, half of 291 studies reached it within 52 months; a quarter within 28 and three quarters within 74.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 19, 2024
First posted
Dec 3, 2024
StartActual
Nov 7, 2024
Primary completionActual
May 6, 2026
CompletionActual
May 6, 2026
Last update
May 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06713564
Lead sponsor
Integro Theranostics
Responsible party
Sponsor
First posted
Dec 3, 2024
Start date
Nov 7, 2024
Primary completion
May 6, 2026
Completion
May 6, 2026
Last update
May 19, 2026

Study contacts

Robert Honigberg, MD
study director · Integro Theranostics

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cronexitide lanocianine

Start the discussion